Page 2502 - Williams Hematology ( PDFDrive )

2473
2472 Index Index 2473

in mantle cell lymphoma, 237t Nuclear translocation, 251 retinal hemorrhages, 8
in splenic marginal zone lymphoma, 1666 Nucleoid, 1843 in sickle cell disease, 772
in T-cell acute lymphoblastic leukemia, Nucleoside phosphorylase, 692t in Waldenström macroglobulinemia, 1791,
186, 233t, 1508, 1508t, 1513t Nucleosome remodeling and deacetylation 1792
prognosis and, 1521 factor (NuRD), 166 ODC (ornithine decarboxylase), 200, 238
Notch activation, 270 Nucleosome remodeling factor (NURF), Odo-leukemias, 1342
Notch ligands, 266, 1155 167 Ofatumumab, 344
Notch signaling, 1155–1156 Nucleotide-binding oligomerization domain adverse effects, 343t, 1536
NPC1/2, 1129 (NOD)-like receptors (NLRs), for chronic lymphocytic leukemia, 1536,
NPM1 298–299, 299f, 1063, 1065f 1540
in acute myelogenous leukemia, 181, 181t, Nucleotide-binding oligomerization domain mechanism of action, 343t
226t, 363, 1280, 1377, 1378t, 1383, (NOD) pathway, 299–300, 301f 2OG (2-oxoglutarate, α-ketoglutarate), 169,
1415 Nucleotides 170
detecting mutations in, 1415 in erythrocytes, 470t, 699 Oil-in-water emulsions, 422
in myelodysplastic syndromes, 181t, 1346 in neutrophils, 935, 935t Ok blood group/antigens, 2332t, 2337
NPM-ALK, 1698 Null phenotypes, 2340–2343 Older persons, 129–137
NR4A receptors, 2284 Null phenotypes, diseases associated with, acute myelogenous leukemia in
Nramp1 (SLC11A1), 621, 1010, 1014 2341–2342t biologic features, 1408
Nramp2. See Divalent metal transporter NuRD (nucleosome remodeling and incidence, 1375, 1375f
(DMT)-1 deacetylation factor), 166 treatment, 1408–1409
NRAS (N-RAS) NURF (nucleosome remodeling and factor), coagulant and anticoagulant factors in,
in acute myelogenous leukemia, 227t, 167 135
1376, 1378t, 1383 Nutritional deficiencies coagulation dysregulation and frailty in,
in chronic myelogenous leukemia cobalamin. See Cobalamin deficiency 137
transformation, 1464 folate. See Folate deficiency C-reactive protein in, 135
in chronic myelomonocytic leukemia, history of, 7 endothelial vasodilation in, 2283
1468 iron. See Iron deficiency erythrocytes in, 134
in myelodysplastic syndromes, 228t, 1346t, lymphocytopenia and, 1206 erythropoietin levels in, 134
1348, 1352 neutropenia and, 994–995 functional decline in, 129–130
in myeloma, 188, 233t, 1709, 1759 thrombocytopenia and, 1997–1998 hematopoiesis in, 132–134
in pure red cell aplasia, 543 NY-ESO-1, 412 hematopoietic cell transplantation in,
NRF-1 (nuclear regulatory factor-1), 894 361–362
NRF2 (nuclear respiratory factor-2), 196 O hematopoietic microenvironment in,
NSAIDs O -methylguanine-DNA methyltransferase 267
6
antiplatelet effects, 404, 2075 (MGMT), 442 immunity and, 135–136, 136f
for mastocytosis, 977 Obatoclax (GX15–070), 1403 inflammation and frailty in, 137
for polyarteritis nodosa, 2106 Obesity leukocytes in, 134
for sickle cell disease pain, 767 acute myelogenous leukemia and, 1374 lymphoma incidence in, 1570, 1570f
NSCs (neural stem cells), 451 lymphoma and, 1573 neutrophil motility in, 1026
NSF (NEM-sensitive fusion protein), 1016 myeloma and, 1734 platelets in, 134–135
NSP4 (neutrophil serine protease 4), 1012t Obinutuzumab, 344–345 primary myelofibrosis in, 1319
NSTEMI (non-ST elevation myocardial adverse effects, 343t, 1536 prothrombotic state in, 135
infarction), 2296. See also for chronic lymphocytic leukemia, 1536, Olfactomedin 4 (OLFM4), 1012t, 1014
Myocardial infarction (MI) 1540, 1645 Olfactory hallucinations, history of, 5
NTPDases, 1886 mechanism of action, 343t Oligoblastic myelogenous leukemia
NTR (neutrophil turnover rate), 941, 942, Obstetric complications. See Pregnancy (refractory anemia with excess
942t Obstructive sleep apnea, 872, 876 blasts)
NTRK3, 233t OCT-1, 1456 acute myelogenous leukemia and, 1280,
NTX, 1738 OCT2 (POU2F2), 235t 1374–1385
Nuclear-cytoplasmic asynchrony, 593 Ocular disorders characteristics, 1343, 1343t
Nuclear factor kappa-B. See NF-κB in antiphospholipid syndrome, 2241 chromosomal abnormalities, 178
Nuclear factor of activated T cells (NFATs), in essential monoclonal gammopathy, definition, 1277
1178, 1528 1724 history, 1343
Nuclear receptors, 250 history of, 5 vs. primary myelofibrosis, 1327
Nuclear regulatory factor-1 (NRF-1), 894 primary lymphomas, 1571, 1574, transition to other clonal myeloid diseases,
Nuclear respiratory factor-2 (NRF2), 196 1579–1581, 1665 1280

Kaushansky_index_p2393-2506.indd 2473 9/21/15 3:22 PM